20.500.12556/DiRROS-27878 The variable use of heparin through intravenous bolus and flush fluid systems during endovascular stroke treatment, a world-wide survey insights from instrumental, neuro-psychological and study-related profiles Background The total amount of heparin administered through flush fluids in stroke patients is not considered in recent trials, possibly influencing main results. We investigated the use of heparin among treating physicians worldwide. Methods We conducted a survey from November 2022 to January 2023 to identify the variability of heparin administration during stroke endovascular treatment (EVT). We calculated the total heparin dose per hour (IU/h) by adding the intravenous (IV)-bolus dose to the amount administered through flush fluids, calculated by a multiplication of the number of infusion bags, drip rate[mL/h] and heparin concentration[IU/L]. Results A total of 315 participants from different countries worldwide completed the survey and 231/315(73%) respondents administer heparin during EVT. The majority administered heparin only through flush fluids (168/231; 72.7%), followed by both IV-bolus and flush fluids (36/231; 16%), and those who used only an IV-bolus (27/231; 11.7%). From the participants that administer heparin through flush fluids, the median heparin concentration was 2000 IU/L (range:100 IU/L-10000 IU/L). The total heparin dose (administered through flush fluids and IV-bolus) among 23 respondents showed a median of 4650 IU/h (IQR:3432–5900). Among the respondents who administer heparin through IV-bolus only, the median was 5250 IU (IQR:3750–7500). Conclusion This survey revealed variable heparin doses administered by physicians worldwide during EVT and reflects the lack of international guidelines. Caution is warranted, specifically during complex/long EVT procedures. Furthermore, heparin flush doses should be considered in future trials regarding periprocedural anticoagulants, since imbalances could potentially confound results. heparin endovascular treatment stroke true false true Angleški jezik Ni določen Neznano 2026-02-26 14:08:37 2026-02-26 14:08:38 2026-02-27 03:58:44 0000-00-00 00:00:00 2025 0 0 Nasl. z nasl. zaslona; Opis vira z dne 27. 3. 2025; 1 spletni vir (1 datoteka PDF (7 str.) issue 17 Vol. 8 March 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 61 2520-8934 10.1186/s42155-025-00532-3 230466051 RAZ_Frol_Senta_2025.pdf RAZ_Frol_Senta_2025.pdf 1 2C3B83FB633EBCF3E0D3F931AE0BADB4 fa84d0fe7e890654d66f98b7044f8a3e0a3c389f5fbaa447658831b230c39e05 713a99b3-1314-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=41027 https://cvirendovasc.springeropen.com/articles/10.1186/s42155-025-00532-3#citeas 1 44d911f9-1314-11f1-9cb0-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=41026 Univerzitetni klinični center Ljubljana 0 0 0